{
    "nctId": "NCT01448447",
    "briefTitle": "Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml\u00ae",
    "officialTitle": "Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml\u00ae Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Ductal Carcinoma in Situ",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Ipsilateral Recurrence Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women,age of at least 45 years\n* Zubrod performance status of 0-2\n* AJCC Stage I-II (T1-T2, N0 M0) breast cancer\n* Maximum tumor dimension \\< 3 cm\n* Invasive ductal, medullary, papillary, tubular, colloid (mucinous) histologies\n* Unifocal breast cancer\n* Unilateral breast cancer (no synchronous or previous contralateral breast cancer)\n* Lumpectomy with negative surgical margins by at least 2 mm or re-excision specimen with negative surgical margins by at least 2 mm\n* Ductal Carcinoma In-Situ\n* Negative axillary lymph nodes for invasive breast cancer (sentinel node biopsy or standard level I-II dissection with \\> 6 nodes removed)\n* Time interval from final breast surgery to brachytherapy loading less than 8 weeks\n* At least 2 mm of breast tissue between the skin and the MammoSite\u00ae balloon surface(prefer \\> 5 mm)\n* If chemotherapy is planned, it must begin no earlier that 2 weeks following completion of radiation therapy. If chemotherapy is first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation therapy.\n* Signed study-specific consent form\n\nExclusion Criteria:\n\n* Invasive lobular histology\n* Non-epithelial breast malignancies such as sarcoma or lymphoma\n* Multifocal or multicentric invasive carcinoma\n* Extensive intraductal component (EIC)\n* Paget's disease of the nipple\n* Skin involvement by tumor, regardless of tumor size\n* Positive axillary lymph nodes\n* Distant metastases\n* Collagen vascular disease (scleroderma)\n* Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females (negative pregnancy test for women of child-bearing age)\n* Any previously treated or synchronous contralateral breast carcinoma\n* Patients with psychiatric or addictive disorder that would preclude obtaining informed Consent\n* Men",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}